R&D/Clinical Trials

Rena Denoncourt, chief operating officer at Corsera Health, discusses the operational challenges of building a startup and how she balances prioritization with the flexibility drug development demands.

Dr. Nick Botwood, chief medical officer and head of research and development at Syndax Pharmaceuticals, draws on his career to explain what separates good R&D organizations from great ones.

Silence Therapeutics and AbCellera launched respective common share public offerings, and Beyang Therapeutics and Remepy closed $30+ million oversubscribed Series A rounds.

BeOne Medicines and Revolution Medicines enter a two-part deal pairing BeOne's PRMT5 inhibitor and EGFR×MET trispecific antibody with Revolution's four clinical RAS(ON) inhibitors.

Platelet count alone can't define ITP treatment success—and what multi-pathway immune targeting actually requires.

Such enterprises will be defined not only by breakthrough therapies but also by agile leadership, AI-enabled transformation and patient-centered operating models that accelerate innovation into real-world impact.

Novo Nordisk selects AWS as its preferred AI partner for drug discovery, Innate Pharma partners with Sobi, and Innovent Biologics secures exclusive commercialization rights for Vanflyta in China.

CSPC Pharmaceutical and AstraZeneca have formed a 51:49 joint venture to build a biologics manufacturing facility in Shijiazhuang.

As multispecific antibodies and antibody drug conjugates outgrow legacy LIMS and ELN platforms, drug developers face a problem more costly than fragmented workflows: scientific reasoning evaporates at every handoff, forcing the next team to start from scratch.

Clinical trials now generate 5.9 million datapoints per Phase III protocol — and most sponsors are still managing them manually.

FDA's advisory committee voted 10 to 3 that efficacy data from the Ignyte study is evaluable and clinically meaningful.

Johnson & Johnson moves to acquire Sail Biomedicines, Processa acquires Vidya Therapeutics, and Relation partners with GSK on AI-driven target discovery collaboration.

An FDA advisory panel voted to recommend six of seven unapproved peptides for compounding access, raising concerns about its newly appointed members.

The shift from looking at lots of possibilities to focusing on specific ones in a drug discovery pipeline is why traditional pipelines don’t work well.

BioMarin and n-Lorem Foundation have partnered to develop the first ASO therapy targeting ReNU syndrome.

TruTechnologies chairman and co-founder argues that while Operation TrialBlazer is directionally correct in targeting regulatory friction, it misses the larger problem.

Dr. Stoehr, neuroscience researcher at AbbVie discusses how biomarkers are opening a new window into Parkinson’s disease.

Eli Lilly's Retatrutide met primary endpoints in two Phase III trials, delivering up to 22.6% body weight loss in adults with severe obesity and cardiovascular disease.

AI adoption in pharma drops sharply in the domains that matter most for discovery.

Robert Allen, Ph.D., Chief Scientific Officer, outlines how the company's Invymab platform uses viral surveillance and predictive modeling to design monoclonal antibodies against likely future variants rather than current strains.

Eli Lilly has agreed to acquire AtaiBeckley for up to $3.8 billion, adding a pipeline of neuroplastogen-based treatments.

Insilico Medicine and Bora Pharmaceuticals entered a strategic alliance to pair Insilico's AI drug discovery platform with Bora's development and manufacturing infrastructure.

AstraZeneca acquires global rights to approved EGFR exon 20 inhibitor Zegfrovy, Chai Discovery strikes an undisclosed AI antibody collaboration with Novartis, and Innovent Biologics licenses its CD40L antibody IBI355 to Spero Therapeutics.

Insilico Medicine has deepened its partnership with China Medical System Holdings with a second CNS-focused collaboration in three months, pairing Insilico's PandaOmics-identified mechanism with CMS's clinical and commercial infrastructure in a deal worth up to $177 million in milestones.

AstraZeneca's Wainua failed to meet the primary endpoint of a late-stage trial in transthyretin-mediated amyloid cardiomyopathy, sending shares down nearly 10% in their largest single-day decline since late 2024.